Generic Name and Formulations:
Cetrorelix (as acetate) 0.25mg, 3mg; per vial; pwd for SC inj after reconstitution.
EMD Serono, Inc.
Indications for CETROTIDE:
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for in vitro fertilization.
Give by SC inj into lower abdominal wall during early to mid-follicular phase; see literature. 3mg once on stimulation day 7, or 0.25mg daily beginning on stimulation day 5 or 6 and continuing until day of hCG administration.
Pregnancy (Cat.X). Nursing mothers.
Do complete gynecological and endocrinological exam first.
Ovarian hyperstimulation syndrome, nausea, headache, inj site reactions, elevated enzymes (eg, ALT, alkaline phosphatase).
Vials 0.25mg (w. diluent)—1
3mg (w. diluent)—1
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|